Graduates

Prenosis, EnterpriseWorks startup graduate, has earned a place on TIME’s Best Inventions of the Year list for its innovative Sepsis ImmunoScore. Sepsis ImmunoScore is an AI diagnostic tool transforming sepsis care—a critical need in U.S. hospitals, where nearly 1.7 million patients are affected annually. The system analyzes 22 health metrics, including vital signs and blood measurements, to provide a rapid sepsis risk score, helping doctors diagnose and predict severe cases within 24 hours. “The Sepsis ImmunoScore is setting a new standard of proactive sepsis care—where faster and more accurate prediction and diagnosis is essential to saving lives,” CEO and co-founder Bobby Reddy Jr. said in a press release. “We are honored to be recognized by TIME for the potential of our work to improve patient outcomes and to bring precision medicine to acute care.” Reddy was also recently honored as one of Crain’s Chicago Business 40 Under 40, a recognition given to executives, founders, creators, and strategists driving change and innovation in the Chicago area. Prenosis was an EnterpriseWorks tenant from 2017 to 2018. Founder Rashid Bashir, Dean of Grainger College of Engineering and Research Park Board of Managers member, developed these technologies with his research group in the Micro and Nanotechnology Laboratory, along with Bobby Reddy Jr. While at the Research Park, the Prenosis team earned a second-place prize in the 14th Annual Dale V. Cozad New Venture Competition. For more information, visit the Prenosis website

EnterpriseWorks graduate Prenosis recently announced the approval of its artificial intelligence-powered diagnostic tool for sepsis by the U.S. Food and Drug Administration. Sepsis occurs when the body has an extreme response to an infection, and it is often deadly. It is notoriously challenging to diagnose, but early detection is key since patients can deteriorate quickly. Prenosis’ diagnostic tool, called Sepsis ImmunoScore, uses 22 different parameters such as temperature, heart rate and cell counts to help clinicians assess a patient’s risk of sepsis. Prenosis was an EnterpriseWorks tenant from 2017 to 2018. Founder Rashid Bashir, Dean of Grainger College of Engineering, developed these technologies with his research group in the Micro and Nanotechnology Laboratory, along with Bobby Reddy. During its time at the Research Park, the Prenosis team earned a second-place prize in the 14th Annual Dale V. Cozad New Venture Competition. Now based in Chicago, Prenosis has been a longtime client of the Illinois FAST Center. Prenosis’ goal is to detect and prevent the majority of diseases before debilitating symptoms present themselves. By integrating biomarkers and clinical data, its diagnostics present real-time critical information, predicts future outcomes for patients, and expedites the delivery of optimal therapy. Prenosis’ approach stands out for its regulatory compliance and focus on safety and efficacy. The company plans to conduct further studies to demonstrate the tool’s accuracy and impact on clinical decision-making, with intentions to market it globally. “FDA authorization of a sepsis diagnostic tool with significant predictive power is a landmark event for people that could ever be at risk of sepsis at some point in their lives,” said Bobby Reddy, Jr, Ph.D. Read more on the CNBC newspage.